Predict your next investment

Corporation
decibio.com

See what CB Insights has to offer

About DeciBio

DeciBio is a strategy consulting and market intelligence firm focused on precision medicine. DeciBio offers advisory services for growth planning, market and opportunity assessment, product and portfolio strategy, and corporate due diligence. The company also offers market intelligence products, including data visualization and analysis platforms and reports relating to immuno-oncology, liquid biopsy, cancer biomarkers, and more.

DeciBio Headquarter Location

10250 Constellation Blvd #100

Los Angeles, California, 90067,

United States

310-451-4510

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest DeciBio News

DeciBio Analytics Launches DxBooks Databases

Mar 24, 2021

Share DeciBio Analytics, the market intelligence subsidiary of DeciBio Consulting, has launched the 2021 edition of the DxBooks. These clinical diagnostic databases include the Infectious Disease DxBook, the Oncology DxBook, and the SARS-CoV-2 DxBook. Formerly known as the Emmes Databases, the DxBooks cover molecular diagnostic testing practices at over one thousand hospital, reference, and public health labs in the U.S. Each database provides detailed quantitative and qualitative information about labs’ diagnostic testing practices, including test adoption, kits and platforms utilized, testing volumes, trends, and more. DxBooks’ web-based Tableau interfaces complement the raw data sets by intuitively facilitating point-and-click data slicing and quick insights. The flagship Infectious Disease DxBook covers 31 assays (both single-analyte and multi-plex panels) in 1,000 U.S. labs, beginning as early as 2016. The Oncology DxBook covers 26 oncology biomarkers across 300 institutions, beginning as early as 2017. Finally, the SARS-CoV-2 DxBook, newly launched in 2020, covers SARS-CoV-2 diagnostic and serology testing practices and forecasts, based on semi-annual interviews with 400 U.S. labs. Related Posts “These databases remain a valuable tool for our subscriber clients as well as for DeciBio’s bespoke strategic consulting practice. We’ve seen clients make great use of this data for sales and marketing, portfolio prioritization, product development, and other uses across the diagnostics space,” says David Cavanaugh, co-founder of DeciBio Consulting. “This simultaneous rebrand and re-launch maintains the same level of high-quality data collection that our clients have relied on for years, while bringing the product identity fully into the DeciBio suite,” notes Julia Daniel, product manager for the DxBooks. The DxBooks databases are available off-the-shelf on an annual subscription basis or as part of DeciBio Consulting’s custom strategic consulting projects.

DeciBio Acquisitions

1 Acquisition

DeciBio acquired 1 company. Their latest acquisition was Emmes - Molecular Diagnostics Testing & Oncology Databases on September 20, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/20/2019

Acquired Unit

5

Date

9/20/2019

Investment Stage

Companies

Valuation

Total Funding

Note

Acquired Unit

Sources

5

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.